Study of Intralesional FLD-103 in Subjects With Basal Cell Carcinoma (BCC)

NCT07670858 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Nodular Basal Cell Carcinoma

Interventions

DRUG: Intralesional FLD-103

Sponsor

Feldan Therapeutics